董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jose Carlos Gutierrez Ramos | 女 | Non-Executive Director | 58 | 未披露 | 未持股 | 2021-04-30 |
| Kevin Lee | 男 | Chief Executive Officer and Executive Director | 53 | 250.67万美元 | 未持股 | 2021-04-30 |
| Greg Winter | 男 | Non-Executive Director | 70 | 13.58万美元 | 未持股 | 2021-04-30 |
| Janice Bourque | 女 | Non-Executive Director | 64 | 20.64万美元 | 未持股 | 2021-04-30 |
| Veronica Jordan | 女 | Non-Executive Director | 70 | 14.98万美元 | 未持股 | 2021-04-30 |
| Richard Kender | 男 | Non-Executive Director | 65 | 23.99万美元 | 未持股 | 2021-04-30 |
| Pierre Legault | 男 | Director and Non-Executive Chairman of the Board of Director | 60 | 38.97万美元 | 未持股 | 2021-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin Lee | 男 | Chief Executive Officer and Executive Director | 53 | 250.67万美元 | 未持股 | 2021-04-30 |
| Lee Kalowski | 男 | President and Chief Financial Officer | 40 | 114.18万美元 | 未持股 | 2021-04-30 |
| Michael Skynner | 男 | Chief Operating Officer | 52 | 115.47万美元 | 未持股 | 2021-04-30 |
| Nigel Crockett | 男 | Chief Business Officer | 56 | 139.96万美元 | 未持股 | 2021-04-30 |
| Nicholas Keen | 男 | Chief Scientific Officer | 53 | 未披露 | 未持股 | 2021-04-30 |
| Dominic Smethurst | 男 | Chief Medical Officer | 47 | 175.99万美元 | 未持股 | 2021-04-30 |
| Pierre Legault | 男 | Director and | 60 | 38.97万美元 | 未持股 | 2021-04-30 |
董事简历
中英对照 | 中文 | 英文- Jose Carlos Gutierrez Ramos
-
Jose Carlos Gutierrez Ramos自2020年12月加入Danaher 以来，一直担任高级副总裁兼首席科学官。在加入Danaher 之前，Gutierrez-Ramos博士于2020年1月至2020年12月担任生物制药公司AbbVie，Inc.的药物发现副总裁；于2018年8月至2020年1月担任生物技术公司Repertoire Immune Medicines的总裁兼首席执行官；于2015年8月至2018年8月担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。
Jose Carlos Gutierrez Ramos,has served as Senior Vice President – Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President – Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020. - Jose Carlos Gutierrez Ramos自2020年12月加入Danaher 以来，一直担任高级副总裁兼首席科学官。在加入Danaher 之前，Gutierrez-Ramos博士于2020年1月至2020年12月担任生物制药公司AbbVie，Inc.的药物发现副总裁；于2018年8月至2020年1月担任生物技术公司Repertoire Immune Medicines的总裁兼首席执行官；于2015年8月至2018年8月担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。
- Jose Carlos Gutierrez Ramos,has served as Senior Vice President – Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President – Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020.
- Kevin Lee
-
Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
Kevin Lee is currently a member of our Board and has been nominated for re election as a director. If re elected, he will hold office from the date of his re-election until the third anniversary of the AGM occurring in 2024 where he must retire by rotation and offer himself for re election, or until his earlier death, resignation or removal.Dr. Lee has served as our Chief Executive Officer and a member of our Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020. - Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
- Kevin Lee is currently a member of our Board and has been nominated for re election as a director. If re elected, he will hold office from the date of his re-election until the third anniversary of the AGM occurring in 2024 where he must retire by rotation and offer himself for re election, or until his earlier death, resignation or removal.Dr. Lee has served as our Chief Executive Officer and a member of our Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020.
- Greg Winter
-
Greg Winteris FRS是我们的联合创始人，自我们成立以来一直担任我们的董事会成员。Greg爵士从1981年到2012年担任英国剑桥医学研究委员会分子生物学实验室（Medical Research Council Laboratory of Molecular Biology LMB）的工作人员，担任副主任和代理主任。他目前是剑桥大学三一学院的院士，此前曾于2012年10月至2019年6月担任剑桥大学三一学院硕士。Greg爵士还担任生物技术公司的顾问。格雷格爵士是英国皇家学会会员，于2004年因对科学的贡献而被封为爵士。2018年，格雷格爵士（Sir Greg）因开发噬菌体显示器（英语:Phage display）用于抗体和肽的定向进化以生产新药而获得诺贝尔化学奖。2016年至2018年，他一直担任BioSceptre International Limited的代理主席。Greg爵士曾是Cambridge Antibody Technology和Domantis的创始人和非执行董事。
Greg Winter is our Co-Founder and has served on of our Board since our inception. Sir Greg was a member of staff of the Medical Research Council Laboratory of Molecular Biology LMB in Cambridge, U.K. from 1981 to 2012 serving as both Deputy and Acting Director. He is currently a Fellow of Trinity College, Cambridge and was previously a Master of Trinity College, Cambridge from October 2012 to June 2019. Sir Greg also serves as a consultant to biotechnology companies. Sir Greg is a Fellow of the Royal Society and was knighted in 2004 for services to science. In 2018 Sir Greg was awarded a Nobel Prize in Chemistry for his work in developing phage display for the directed evolution of antibodies and peptides to produce new medicines. He has been the Acting Chairman of Biosceptre International Limited from 2016 to 2018. Sir Greg was a founder and non-Executive Director of Cambridge Antibody Technology and Domantis. - Greg Winteris FRS是我们的联合创始人，自我们成立以来一直担任我们的董事会成员。Greg爵士从1981年到2012年担任英国剑桥医学研究委员会分子生物学实验室（Medical Research Council Laboratory of Molecular Biology LMB）的工作人员，担任副主任和代理主任。他目前是剑桥大学三一学院的院士，此前曾于2012年10月至2019年6月担任剑桥大学三一学院硕士。Greg爵士还担任生物技术公司的顾问。格雷格爵士是英国皇家学会会员，于2004年因对科学的贡献而被封为爵士。2018年，格雷格爵士（Sir Greg）因开发噬菌体显示器（英语:Phage display）用于抗体和肽的定向进化以生产新药而获得诺贝尔化学奖。2016年至2018年，他一直担任BioSceptre International Limited的代理主席。Greg爵士曾是Cambridge Antibody Technology和Domantis的创始人和非执行董事。
- Greg Winter is our Co-Founder and has served on of our Board since our inception. Sir Greg was a member of staff of the Medical Research Council Laboratory of Molecular Biology LMB in Cambridge, U.K. from 1981 to 2012 serving as both Deputy and Acting Director. He is currently a Fellow of Trinity College, Cambridge and was previously a Master of Trinity College, Cambridge from October 2012 to June 2019. Sir Greg also serves as a consultant to biotechnology companies. Sir Greg is a Fellow of the Royal Society and was knighted in 2004 for services to science. In 2018 Sir Greg was awarded a Nobel Prize in Chemistry for his work in developing phage display for the directed evolution of antibodies and peptides to produce new medicines. He has been the Acting Chairman of Biosceptre International Limited from 2016 to 2018. Sir Greg was a founder and non-Executive Director of Cambridge Antibody Technology and Domantis.
- Janice Bourque
-
Janice Bourque自2019年7月起担任董事会成员。Bourque女士是Hercules Capital生命科学集团的常务董事，拥有超过25年的生命科学经验，专注于新兴成长阶段公司。在此之前，Bourque女士曾为Commons Capital提供咨询，担任Comerica Bank的高级副总裁和生命科学集团负责人，并担任马萨诸塞州生物技术委员会主席兼首席执行官。Bourque女士目前在Poxel，SA和The Village Bank的董事会任职。Bourque女士还担任麻省理工学院科赫综合癌症研究所（MIT Koch Institute for Integrative Cancer Research）的董事会成员。她持有the University of New Hampshire的兽医科学B.S.和财务和会计工商管理硕士学位。
Janice Bourque has served as a member of our Board since July 2019. Ms. Bourque is a Managing Director in Hercules Capital's life sciences group and has more than 25 years of life science experience and a focus on emerging growth stage companies. Previously, Ms. Bourque has consulted for Commons Capital, served as Senior Vice President and Group Head Life Sciences at Comerica Bank and was President and Chief Executive Officer of the Massachusetts Biotechnology Council. Ms. Bourque currently serves on the board of directors of Poxel, SA and the Village Bank. Ms. Bourque has also served on the board of directors of the MIT Koch Institute for Integrative Cancer Research. She holds a B.S. in veterinary science and an MBA in finance and accounting from the University of New Hampshire. - Janice Bourque自2019年7月起担任董事会成员。Bourque女士是Hercules Capital生命科学集团的常务董事，拥有超过25年的生命科学经验，专注于新兴成长阶段公司。在此之前，Bourque女士曾为Commons Capital提供咨询，担任Comerica Bank的高级副总裁和生命科学集团负责人，并担任马萨诸塞州生物技术委员会主席兼首席执行官。Bourque女士目前在Poxel，SA和The Village Bank的董事会任职。Bourque女士还担任麻省理工学院科赫综合癌症研究所（MIT Koch Institute for Integrative Cancer Research）的董事会成员。她持有the University of New Hampshire的兽医科学B.S.和财务和会计工商管理硕士学位。
- Janice Bourque has served as a member of our Board since July 2019. Ms. Bourque is a Managing Director in Hercules Capital's life sciences group and has more than 25 years of life science experience and a focus on emerging growth stage companies. Previously, Ms. Bourque has consulted for Commons Capital, served as Senior Vice President and Group Head Life Sciences at Comerica Bank and was President and Chief Executive Officer of the Massachusetts Biotechnology Council. Ms. Bourque currently serves on the board of directors of Poxel, SA and the Village Bank. Ms. Bourque has also served on the board of directors of the MIT Koch Institute for Integrative Cancer Research. She holds a B.S. in veterinary science and an MBA in finance and accounting from the University of New Hampshire.
- Veronica Jordan
-
Veronica Jordan自2019年10月起担任董事会成员。Jordan博士担任Corporate Director超过15年，在生物制药行业拥有丰富的经验，并一直担任开发新型梦百合产品的公司的顾问。自2007年以来，乔丹博士一直担任梦百合公司和合同研究组织的独立顾问，并担任天使投资者网络Golden Seeds的董事总经理。她此前曾担任Medelle Corporation（私人医疗设备公司）的首席执行官兼总裁，也曾担任Parexel International公司的多种执行职务（任职公司的管理团队14年）。Jordan博士自2014年以来一直担任Vermillion，Inc.的董事会成员。从2006年到2016年，她是Albany MolecularResearch，Inc.的董事会成员Jordan博士在剑桥大学（Cambridge University）获得生物化学学士学位，在牛津大学（Oxford University）获得生物化学和细胞生物学博士学位。
Veronica Jordan has served as a member of our Board since October 2019. Dr. Jordan has been a corporate director for more than 15 years, with extensive experience in the biopharmaceutical industry, and has been an advisor to companies developing novel healthcare products. Since 2007 Dr. Jordan has served as an independent consultant to healthcare companies and contract research organizations and as Managing Director of Golden Seeds, an angel investor network. She was previously CEO and President of Medelle Corporation, a private medical device company, and held various executive roles at PAREXEL International during her 14 years on the company's management team. Dr. Jordan has been a member of the board of directors of Aspira Women's Health, Inc. formerly Vermillion, Inc. since 2014. From 2006 to 2016 she was a member of the board of directors of Albany Molecular Research, Inc. Dr. Jordan earned a B.A. in biochemistry from Cambridge University and a Ph.D. in biochemistry and cell biology from Oxford University. - Veronica Jordan自2019年10月起担任董事会成员。Jordan博士担任Corporate Director超过15年，在生物制药行业拥有丰富的经验，并一直担任开发新型梦百合产品的公司的顾问。自2007年以来，乔丹博士一直担任梦百合公司和合同研究组织的独立顾问，并担任天使投资者网络Golden Seeds的董事总经理。她此前曾担任Medelle Corporation（私人医疗设备公司）的首席执行官兼总裁，也曾担任Parexel International公司的多种执行职务（任职公司的管理团队14年）。Jordan博士自2014年以来一直担任Vermillion，Inc.的董事会成员。从2006年到2016年，她是Albany MolecularResearch，Inc.的董事会成员Jordan博士在剑桥大学（Cambridge University）获得生物化学学士学位，在牛津大学（Oxford University）获得生物化学和细胞生物学博士学位。
- Veronica Jordan has served as a member of our Board since October 2019. Dr. Jordan has been a corporate director for more than 15 years, with extensive experience in the biopharmaceutical industry, and has been an advisor to companies developing novel healthcare products. Since 2007 Dr. Jordan has served as an independent consultant to healthcare companies and contract research organizations and as Managing Director of Golden Seeds, an angel investor network. She was previously CEO and President of Medelle Corporation, a private medical device company, and held various executive roles at PAREXEL International during her 14 years on the company's management team. Dr. Jordan has been a member of the board of directors of Aspira Women's Health, Inc. formerly Vermillion, Inc. since 2014. From 2006 to 2016 she was a member of the board of directors of Albany Molecular Research, Inc. Dr. Jordan earned a B.A. in biochemistry from Cambridge University and a Ph.D. in biochemistry and cell biology from Oxford University.
- Richard Kender
-
Richard Kender自2019年7月起担任董事会成员。Kender先生在制药行业拥有广泛的职业生涯，最近于2000年至2013年退休期间担任默克制药公司业务发展和公司许可高级副总裁。在Merck的职业生涯中，Kender先生在支持国内和国际研究，商业和制造部门的业务开发，许可和财务角色方面具有很大的影响力。Kender先生目前在Seres Therapeutics的董事会和审计委员会任职，并在Poxel SA的董事会和审计委员会任职。Kender先生在维拉诺瓦大学（Villanova University）获得会计学学士学位，并在费尔利·迪金森大学（Fairleigh Dickinson University）获得工商管理硕士学位。
Richard Kender has served as a member of our Board since July 2019. Mr. Kender had an extensive career in the pharmaceutical industry, most recently serving as Senior Vice President of Business Development and Corporate Licensing at Merck & Co., Inc. from 2000 until his retirement in 2013. During his career at Merck, Mr. Kender was greatly influential across Business Development, Licensing and in finance roles that supported the domestic and international research, commercial and manufacturing divisions. Mr. Kender currently serves on the board of directors and Audit Committee of Seres Therapeutics and on the board of directors and Audit Committee of Poxel SA. Mr. Kender earned his B.S. in accounting from Villanova University and his MBA from Fairleigh Dickinson University. - Richard Kender自2019年7月起担任董事会成员。Kender先生在制药行业拥有广泛的职业生涯，最近于2000年至2013年退休期间担任默克制药公司业务发展和公司许可高级副总裁。在Merck的职业生涯中，Kender先生在支持国内和国际研究，商业和制造部门的业务开发，许可和财务角色方面具有很大的影响力。Kender先生目前在Seres Therapeutics的董事会和审计委员会任职，并在Poxel SA的董事会和审计委员会任职。Kender先生在维拉诺瓦大学（Villanova University）获得会计学学士学位，并在费尔利·迪金森大学（Fairleigh Dickinson University）获得工商管理硕士学位。
- Richard Kender has served as a member of our Board since July 2019. Mr. Kender had an extensive career in the pharmaceutical industry, most recently serving as Senior Vice President of Business Development and Corporate Licensing at Merck & Co., Inc. from 2000 until his retirement in 2013. During his career at Merck, Mr. Kender was greatly influential across Business Development, Licensing and in finance roles that supported the domestic and international research, commercial and manufacturing divisions. Mr. Kender currently serves on the board of directors and Audit Committee of Seres Therapeutics and on the board of directors and Audit Committee of Poxel SA. Mr. Kender earned his B.S. in accounting from Villanova University and his MBA from Fairleigh Dickinson University.
- Pierre Legault
-
Pierre Legault ，2012十一月以来担任Nephrogenex执行董事长，这是专注治疗糖尿病肾病的制药公司；自2012四月起，担任Stone Management LLC总裁和首席执行官，该公司专注于业务开发和董事协助领域。2010-2012，他是英国中等规模生物技术公司Prosidion Ltd首席执行官，该公司是Astellas Pharmaceuticals的全资子公司。2009-2010他担任另一家中等规模生物技术公司 OSI Pharmaceuticals执行副总裁，首席财务官和财务总监。2007六月至2009，他担任财富500强医药零售公司 Rite Aid Corporation高级执行副总裁和首席行政官。此前，他在赛诺菲-安万特公司及其前身公司担任了多个高级职务，任期超过15年。最近的职务是该公司大型全球业务部的全球总裁，任期2003至2005。之前曾担任的职务包括，2000-2003，安万特制药高级副总裁，代理首席执行官；1998-2000， Hoechst Marion Roussel财务全球高级副总裁，财务总监；1997-1998，Marion Merrell Dow北美区财务，IT管理的高级副总裁和首席财务官；1990-1996， Marion Merrell Dow Pharmaceutical加拿大分部的高级副总裁和首席财务官。另外，他仍供职于一些上市公司，私营公司，非营利公司的董事会和审计委员会，以及一些咨询委员会，其中包括：OSI Investment Holdings GMBH （董事长）， 一个风险投资公司（2009-2012）， Cyclacel Pharmaceutical Inc.， 一个上市制药公司（2006-2008）， PJC Inc.， 一个药品销售上市公司（2005-2007）， 以及其它一些董事会。他曾在哈佛商学院，麦克吉尔大学和蒙特利尔大学学习，并拿到了美术和建筑学士学位，工商管理硕士学位，注册会计师资格。
Pierre Legault has served as our chairman and a member of our Board since March 2019. Mr. Legault has served on the board of directors of Urovant Sciences Ltd. as lead director since July 2018 has served on the board of directors of Poxel SA since January 2016 and has been chairman of such board since March 2016 has served on the board of directors and as chairman of the board of Artios Pharma Limited since February 2018 and has served as a director of Syndax Pharmaceuticals, Inc. since January 2017. Mr. Legault has also previously served as a member of the boards of directors at Clementia Pharmaceuticals Inc., Forest Laboratories, Inc., Tobira Therapeutics, Inc., NPS Pharmaceuticals, Inc., Regado Biosciences, Inc., ARMO Biosciences, Inc., Iroko Pharmaceuticals LLC, Cyclacel Pharmaceuticals Inc., Eckerd Pharmacy and NephroGenex, Inc., where he also served as the Chairman and Chief Executive Officer from 2012 to 2016. From 2010 to 2012 Mr. Legault served as the Chief Executive Officer of Prosidion Ltd., a subsidiary of Astellas Pharma Inc., and from 2009 to 2010 he served as the Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Inc. Mr. Legault also previously served as the Chief Executive Officer of Eckerd Pharmacy and Chief Administrative Officer of the Rite Aid Corporation. Between 1989 and 2005 Mr. Legault held various global roles such as President, Chief Executive Officer and Chief Financial Officer at legacy companies of the Sanofi-Aventis group. Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal, an MBA. in Marketing from McGill University and holds C.A. and C.P.A. diplomas. He also studied at Harvard Business School in their Graduate Executive MBA program. - Pierre Legault ，2012十一月以来担任Nephrogenex执行董事长，这是专注治疗糖尿病肾病的制药公司；自2012四月起，担任Stone Management LLC总裁和首席执行官，该公司专注于业务开发和董事协助领域。2010-2012，他是英国中等规模生物技术公司Prosidion Ltd首席执行官，该公司是Astellas Pharmaceuticals的全资子公司。2009-2010他担任另一家中等规模生物技术公司 OSI Pharmaceuticals执行副总裁，首席财务官和财务总监。2007六月至2009，他担任财富500强医药零售公司 Rite Aid Corporation高级执行副总裁和首席行政官。此前，他在赛诺菲-安万特公司及其前身公司担任了多个高级职务，任期超过15年。最近的职务是该公司大型全球业务部的全球总裁，任期2003至2005。之前曾担任的职务包括，2000-2003，安万特制药高级副总裁，代理首席执行官；1998-2000， Hoechst Marion Roussel财务全球高级副总裁，财务总监；1997-1998，Marion Merrell Dow北美区财务，IT管理的高级副总裁和首席财务官；1990-1996， Marion Merrell Dow Pharmaceutical加拿大分部的高级副总裁和首席财务官。另外，他仍供职于一些上市公司，私营公司，非营利公司的董事会和审计委员会，以及一些咨询委员会，其中包括：OSI Investment Holdings GMBH （董事长）， 一个风险投资公司（2009-2012）， Cyclacel Pharmaceutical Inc.， 一个上市制药公司（2006-2008）， PJC Inc.， 一个药品销售上市公司（2005-2007）， 以及其它一些董事会。他曾在哈佛商学院，麦克吉尔大学和蒙特利尔大学学习，并拿到了美术和建筑学士学位，工商管理硕士学位，注册会计师资格。
- Pierre Legault has served as our chairman and a member of our Board since March 2019. Mr. Legault has served on the board of directors of Urovant Sciences Ltd. as lead director since July 2018 has served on the board of directors of Poxel SA since January 2016 and has been chairman of such board since March 2016 has served on the board of directors and as chairman of the board of Artios Pharma Limited since February 2018 and has served as a director of Syndax Pharmaceuticals, Inc. since January 2017. Mr. Legault has also previously served as a member of the boards of directors at Clementia Pharmaceuticals Inc., Forest Laboratories, Inc., Tobira Therapeutics, Inc., NPS Pharmaceuticals, Inc., Regado Biosciences, Inc., ARMO Biosciences, Inc., Iroko Pharmaceuticals LLC, Cyclacel Pharmaceuticals Inc., Eckerd Pharmacy and NephroGenex, Inc., where he also served as the Chairman and Chief Executive Officer from 2012 to 2016. From 2010 to 2012 Mr. Legault served as the Chief Executive Officer of Prosidion Ltd., a subsidiary of Astellas Pharma Inc., and from 2009 to 2010 he served as the Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Inc. Mr. Legault also previously served as the Chief Executive Officer of Eckerd Pharmacy and Chief Administrative Officer of the Rite Aid Corporation. Between 1989 and 2005 Mr. Legault held various global roles such as President, Chief Executive Officer and Chief Financial Officer at legacy companies of the Sanofi-Aventis group. Mr. Legault earned a B.B.A. in Business & International Finance from HEC Montreal, an MBA. in Marketing from McGill University and holds C.A. and C.P.A. diplomas. He also studied at Harvard Business School in their Graduate Executive MBA program.
高管简历
中英对照 | 中文 | 英文- Kevin Lee
Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
Kevin Lee is currently a member of our Board and has been nominated for re election as a director. If re elected, he will hold office from the date of his re-election until the third anniversary of the AGM occurring in 2024 where he must retire by rotation and offer himself for re election, or until his earlier death, resignation or removal.Dr. Lee has served as our Chief Executive Officer and a member of our Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020.- Kevin Lee自2015年9月以来一直担任我们的首席执行官兼董事会成员。2012年4月至2015年9月，李博士担任制药公司辉瑞公司罕见病研究部门的高级副总裁兼首席科学官，2004年11月至2012年4月，李博士在GlaxoSmithKline plc工作，在那里，除了领导形成多个战略商业和学术伙伴关系外，他还领导表观遗传学研究，并负责Epinova Discovery Performance Unit的创建。加入GlaxoSmithKline之前，Lee博士是Warwick University Medical School的讲师，创立了Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum和NeuroSolutions（现Oncosil Medical Ltd ASX）之前，专门开发炎症和代谢性疾病的小分子和多肽疗法。Lee博士在诺丁汉大学（Nottingham University）获得BPHARM，在剑桥大学（Cambridge University）获得药理学博士学位。Lee博士拥有Warwick Business School的工商管理硕士学位，目前担任Nodthera Ltd.的非执行董事，自2018年10月起担任该职位，并自2017年12月起担任Wilbraham Consulting Ltd.的董事。
- Kevin Lee is currently a member of our Board and has been nominated for re election as a director. If re elected, he will hold office from the date of his re-election until the third anniversary of the AGM occurring in 2024 where he must retire by rotation and offer himself for re election, or until his earlier death, resignation or removal.Dr. Lee has served as our Chief Executive Officer and a member of our Board since September 2015. From April 2012 to September 2015 Dr. Lee served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer Inc., a pharmaceutical company. From November 2004 to April 2012 Dr. Lee worked at GlaxoSmithKline plc, where in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GlaxoSmithKline, Dr. Lee was a lecturer at Warwick University Medical School and founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005 and Neurosolutions now Oncosil Medical Ltd ASX. Dr. Lee received a BPharm from Nottingham University and a Ph.D. in pharmacology from Cambridge University. Dr. Lee has an MBA from Warwick Business School and currently serves as a non-executive director for Nodthera Ltd, a position he has held since October 2018 as a director at Wilbraham Consulting Ltd., a position he has held since December 2017 and as a director at Mestag Therapeutics Ltd, a position he has held since September 2020.
- Lee Kalowski
Lee Kalowski自2017年7月起担任我们的首席财务官，自2019年1月起担任我们的总裁。在加入我们之前，Kalowski先生于2014年9月至2016年9月担任Tokai Pharmaceuticals，Inc.的首席财务官，并于2016年9月至2017年5月担任其咨询首席财务官/商务官。纳斯达克股票代码:TKAI，一家生物制药公司。任职Tokai公司之前，他曾担任Credit Suisse公司的全球生物技术股票研究职务（从2010年6月到2014年9月），在那里他曾担任高级分析师（从2011年5月到2014年9月），以及合伙人（从2010年6月到2011年5月）。Kalowski先生在联合学院（Union College）获得生物学与经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
Lee Kalowski has served as our Chief Financial Officer since July 2017 and as our President since January 2019. Prior to joining us, from September 2014 until September 2016 Mr. Kalowski served as the Chief Financial Officer and from September 2016 until May 2017 served as the consulting Chief Financial/Business Officer of Tokai Pharmaceuticals, Inc., a biopharmaceutical company. Prior to Tokai, from June 2010 to September 2014 Mr. Kalowski served in global biotechnology equity research at Credit Suisse, where he covered companies in the biopharmaceutical industry as a Senior Analyst from May 2011 until September 2014 and as an Associate from June 2010 until May 2011. Mr. Kalowski received a B.A. in biology and economics from Union College and an MBA from The Wharton School of the University of Pennsylvania.- Lee Kalowski自2017年7月起担任我们的首席财务官，自2019年1月起担任我们的总裁。在加入我们之前，Kalowski先生于2014年9月至2016年9月担任Tokai Pharmaceuticals，Inc.的首席财务官，并于2016年9月至2017年5月担任其咨询首席财务官/商务官。纳斯达克股票代码:TKAI，一家生物制药公司。任职Tokai公司之前，他曾担任Credit Suisse公司的全球生物技术股票研究职务（从2010年6月到2014年9月），在那里他曾担任高级分析师（从2011年5月到2014年9月），以及合伙人（从2010年6月到2011年5月）。Kalowski先生在联合学院（Union College）获得生物学与经济学学士学位，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
- Lee Kalowski has served as our Chief Financial Officer since July 2017 and as our President since January 2019. Prior to joining us, from September 2014 until September 2016 Mr. Kalowski served as the Chief Financial Officer and from September 2016 until May 2017 served as the consulting Chief Financial/Business Officer of Tokai Pharmaceuticals, Inc., a biopharmaceutical company. Prior to Tokai, from June 2010 to September 2014 Mr. Kalowski served in global biotechnology equity research at Credit Suisse, where he covered companies in the biopharmaceutical industry as a Senior Analyst from May 2011 until September 2014 and as an Associate from June 2010 until May 2011. Mr. Kalowski received a B.A. in biology and economics from Union College and an MBA from The Wharton School of the University of Pennsylvania.
- Michael Skynner
Michael Skynner自2018年1月起担任我们的首席运营官，在此之前，自2016年1月起担任我们的运营Vice President。在加入我们之前，Skynner博士于2013年9月至2016年1月在制药公司辉瑞公司工作，担任罕见疾病联盟负责人，领导欧洲的罕见疾病工作，并创立和运营辉瑞罕见疾病联盟。在加入辉瑞之前，Skynner博士从2008年5月到2013年9月在GlaxoSmithKline plc工作，专注于开发针对炎性激酶的治疗药物。任职GlaxoSmithKline公司之前，Skynner博士于2001年共同创立Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum公司之前，专门开发用于炎症和代谢性疾病的小分子和多肽疗法。Skynner博士在帝国理工学院（Imperial College）获得生物化学博士学位。
Michael Skynner has served as our Chief Operating Officer since January 2018 and prior to this, served as our Vice President of Operations since January 2016. Prior to joining us, Dr. Skynner worked at Pfizer Inc., a pharmaceutical company, from September 2013 to January 2016 where he was Head of Rare Disease Alliances, led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium. Prior to Pfizer, from May 2008 to September 2013 Dr. Skynner worked at GlaxoSmithKline plc, where he focused on developing therapeutics targeting inflammatory kinases. Prior to GlaxoSmithKline, in 2001 Dr. Skynner co-founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005. Dr. Skynner obtained his Ph.D. in biochemistry from Imperial College.- Michael Skynner自2018年1月起担任我们的首席运营官，在此之前，自2016年1月起担任我们的运营Vice President。在加入我们之前，Skynner博士于2013年9月至2016年1月在制药公司辉瑞公司工作，担任罕见疾病联盟负责人，领导欧洲的罕见疾病工作，并创立和运营辉瑞罕见疾病联盟。在加入辉瑞之前，Skynner博士从2008年5月到2013年9月在GlaxoSmithKline plc工作，专注于开发针对炎性激酶的治疗药物。任职GlaxoSmithKline公司之前，Skynner博士于2001年共同创立Cambridge Biotechnology Ltd，该公司在2005年出售给BioVitrum公司之前，专门开发用于炎症和代谢性疾病的小分子和多肽疗法。Skynner博士在帝国理工学院（Imperial College）获得生物化学博士学位。
- Michael Skynner has served as our Chief Operating Officer since January 2018 and prior to this, served as our Vice President of Operations since January 2016. Prior to joining us, Dr. Skynner worked at Pfizer Inc., a pharmaceutical company, from September 2013 to January 2016 where he was Head of Rare Disease Alliances, led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium. Prior to Pfizer, from May 2008 to September 2013 Dr. Skynner worked at GlaxoSmithKline plc, where he focused on developing therapeutics targeting inflammatory kinases. Prior to GlaxoSmithKline, in 2001 Dr. Skynner co-founded Cambridge Biotechnology Ltd, which specialized in developing small molecule and peptide therapeutics for inflammation and metabolic diseases before its trade sale to Biovitrum in 2005. Dr. Skynner obtained his Ph.D. in biochemistry from Imperial College.
- Nigel Crockett
Nigel Crockett自2019年9月起担任我们的首席商务官。从2005年到加入Bicycle，Crockett博士是Tukan Partners，Ltd.的创始合伙人，该公司是一家专门从事生物技术的商业咨询公司。任职Tukan公司之前，他曾担任生命科学领域的商业和业务开发职务，包括Astex Therapeutics公司（总部位于英国剑桥的公司，专注于肿瘤和中枢神经系统中枢神经系统疾病的药物发现和开发）的Vice President和业务开发。Crockett博士在剑桥大学（Cambridge University）获得分子生物学博士学位和理学学士学位。曼彻斯特大学化学学士学位。
Nigel Crockett has served as our Chief Business Officer since September 2019. From 2005 until joining Bicycle, Dr. Crockett was founding partner at Tukan Partners, Ltd., a business consultancy specializing in biotechnology. Prior to Tukan, he held commercial and business development roles within the life sciences sector, including as Vice President, Business Development at Astex Therapeutics, a Cambridge, UK-based company focused on drug discovery and development for oncology and central nervous system CNS disorders. Dr. Crockett earned a Ph.D. in Molecular Biology from Cambridge University and a B.Sc. in Chemistry from the University of Manchester.- Nigel Crockett自2019年9月起担任我们的首席商务官。从2005年到加入Bicycle，Crockett博士是Tukan Partners，Ltd.的创始合伙人，该公司是一家专门从事生物技术的商业咨询公司。任职Tukan公司之前，他曾担任生命科学领域的商业和业务开发职务，包括Astex Therapeutics公司（总部位于英国剑桥的公司，专注于肿瘤和中枢神经系统中枢神经系统疾病的药物发现和开发）的Vice President和业务开发。Crockett博士在剑桥大学（Cambridge University）获得分子生物学博士学位和理学学士学位。曼彻斯特大学化学学士学位。
- Nigel Crockett has served as our Chief Business Officer since September 2019. From 2005 until joining Bicycle, Dr. Crockett was founding partner at Tukan Partners, Ltd., a business consultancy specializing in biotechnology. Prior to Tukan, he held commercial and business development roles within the life sciences sector, including as Vice President, Business Development at Astex Therapeutics, a Cambridge, UK-based company focused on drug discovery and development for oncology and central nervous system CNS disorders. Dr. Crockett earned a Ph.D. in Molecular Biology from Cambridge University and a B.Sc. in Chemistry from the University of Manchester.
- Nicholas Keen
Nicholas Keen自2017年1月起担任我们的首席科学官。在加入我们之前，从2011年4月到2016年12月，基恩博士是诺华制药公司Novartis AG的子公司诺华生物医学研究所剑桥美国办事处肿瘤药物开发主管。从2005年8月到2011年3月，基恩博士在阿斯利康制药公司位于马萨诸塞州沃尔瑟姆的美国研究基地领导早期肿瘤研究小组，在此之前，从1997年1月到2005年7月，他在阿斯利康的英国肿瘤研究小组工作。Keen博士在剑桥大学完成了本科学业，在剑桥的帝国癌症研究基金会完成了研究生学业，并在剑桥的分子生物学实验室完成了博士后研究。
Nicholas Keen has served as our Chief Scientific Officer since January 2017. Prior to joining us, from April 2011 until December 2016 Dr. Keen was the Head of Oncology Drug Discovery at the Cambridge US office of the Novartis Institutes for Biomedical Research (NIBR), a subsidiary of Novartis AG, a pharmaceutical company.Prior to Novartis, from August 2005 to March 2011 Dr. Keen led the early lead generation group for oncology at AstraZeneca plc's US research site in Waltham, Massachusetts, and before this, from January 1997 to July 2005 worked in AstraZeneca's UK oncology research group. Dr. Keen completed his undergraduate studies at the University of Cambridge, his graduate studies at the Imperial Cancer Research Fund in Cambridge and his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.- Nicholas Keen自2017年1月起担任我们的首席科学官。在加入我们之前，从2011年4月到2016年12月，基恩博士是诺华制药公司Novartis AG的子公司诺华生物医学研究所剑桥美国办事处肿瘤药物开发主管。从2005年8月到2011年3月，基恩博士在阿斯利康制药公司位于马萨诸塞州沃尔瑟姆的美国研究基地领导早期肿瘤研究小组，在此之前，从1997年1月到2005年7月，他在阿斯利康的英国肿瘤研究小组工作。Keen博士在剑桥大学完成了本科学业，在剑桥的帝国癌症研究基金会完成了研究生学业，并在剑桥的分子生物学实验室完成了博士后研究。
- Nicholas Keen has served as our Chief Scientific Officer since January 2017. Prior to joining us, from April 2011 until December 2016 Dr. Keen was the Head of Oncology Drug Discovery at the Cambridge US office of the Novartis Institutes for Biomedical Research (NIBR), a subsidiary of Novartis AG, a pharmaceutical company.Prior to Novartis, from August 2005 to March 2011 Dr. Keen led the early lead generation group for oncology at AstraZeneca plc's US research site in Waltham, Massachusetts, and before this, from January 1997 to July 2005 worked in AstraZeneca's UK oncology research group. Dr. Keen completed his undergraduate studies at the University of Cambridge, his graduate studies at the Imperial Cancer Research Fund in Cambridge and his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.
- Dominic Smethurst
Dominic Smethurst自2020年7月起担任我们的首席医疗官。在加入我们之前，从2019年2月至2020年7月，Smethurst博士是一名医学顾问，为生物制药公司的临床开发战略和许可项目提供建议。在此之前，从2016年9月至2018年9月，他担任罗氏收购的免疫肿瘤公司Tusk Therapeutics的首席医疗官。从2015年6月到2016年9月，Smethurst博士在全球合同研究组织ICON担任肿瘤学副总裁和全球治疗领域负责人。在加入ICON之前，他曾在阿斯利康、安进和Adaptimmune担任过医生领导职务。Smethurst博士是皇家内科医学院和药学院的成员。他以优异的成绩获得剑桥大学阿登布鲁克临床学院的MBCHB学位，以及剑桥大学基督学院的文学硕士学位。
Dominic Smethurst has served as our Chief Medical Officer since July 2020. Prior to joining us, from February 2019 to July 2020 Dr. Smethurst was a medical consultant, advising biopharma companies on clinical development strategies and licensing projects. Prior to that, from September 2016 to September 2018 he served as Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche. From June 2015 to September 2016 Dr. Smethurst served as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization. Before Icon, he held physician leadership roles at AstraZeneca, Amgen and Adaptimmune. Dr. Smethurst is a Member of both the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He earned an MBChB with Distinction from Addenbrooke's Clinical School Cambridge, as well as an MA from Christ's College Cambridge.- Dominic Smethurst自2020年7月起担任我们的首席医疗官。在加入我们之前，从2019年2月至2020年7月，Smethurst博士是一名医学顾问，为生物制药公司的临床开发战略和许可项目提供建议。在此之前，从2016年9月至2018年9月，他担任罗氏收购的免疫肿瘤公司Tusk Therapeutics的首席医疗官。从2015年6月到2016年9月，Smethurst博士在全球合同研究组织ICON担任肿瘤学副总裁和全球治疗领域负责人。在加入ICON之前，他曾在阿斯利康、安进和Adaptimmune担任过医生领导职务。Smethurst博士是皇家内科医学院和药学院的成员。他以优异的成绩获得剑桥大学阿登布鲁克临床学院的MBCHB学位，以及剑桥大学基督学院的文学硕士学位。
- Dominic Smethurst has served as our Chief Medical Officer since July 2020. Prior to joining us, from February 2019 to July 2020 Dr. Smethurst was a medical consultant, advising biopharma companies on clinical development strategies and licensing projects. Prior to that, from September 2016 to September 2018 he served as Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche. From June 2015 to September 2016 Dr. Smethurst served as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization. Before Icon, he held physician leadership roles at AstraZeneca, Amgen and Adaptimmune. Dr. Smethurst is a Member of both the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He earned an MBChB with Distinction from Addenbrooke's Clinical School Cambridge, as well as an MA from Christ's College Cambridge.
- Pierre Legault
Pierre Legault ，2012十一月以来担任Nephrogenex执行董事长，这是专注治疗糖尿病肾病的制药公司；自2012四月起，担任Stone Management LLC总裁和首席执行官，该公司专注于业务开发和董事协助领域。2010-2012，他是英国中等规模生物技术公司Prosidion Ltd首席执行官，该公司是Astellas Pharmaceuticals的全资子公司。2009-2010他担任另一家中等规模生物技术公司 OSI Pharmaceuticals执行副总裁，首席财务官和财务总监。2007六月至2009，他担任财富500强医药零售公司 Rite Aid Corporation高级执行副总裁和首席行政官。此前，他在赛诺菲-安万特公司及其前身公司担任了多个高级职务，任期超过15年。最近的职务是该公司大型全球业务部的全球总裁，任期2003至2005。之前曾担任的职务包括，2000-2003，安万特制药高级副总裁，代理首席执行官；1998-2000， Hoechst Marion Roussel财务全球高级副总裁，财务总监；1997-1998，Marion Merrell Dow北美区财务，IT管理的高级副总裁和首席财务官；1990-1996， Marion Merrell Dow Pharmaceutical加拿大分部的高级副总裁和首席财务官。另外，他仍供职于一些上市公司，私营公司，非营利公司的董事会和审计委员会，以及一些咨询委员会，其中包括：OSI Investment Holdings GMBH （董事长）， 一个风险投资公司（2009-2012）， Cyclacel Pharmaceutical Inc.， 一个上市制药公司（2006-2008）， PJC Inc.， 一个药品销售上市公司（2005-2007）， 以及其它一些董事会。他曾在哈佛商学院，麦克吉尔大学和蒙特利尔大学学习，并拿到了美术和建筑学士学位，工商管理硕士学位，注册会计师资格。
Pierre Legault is a Class I director who has served as a member of our board of directors since January 2017. Mr. Legault also serves on the board of Bicycle Therapeutics Chairman, Poxel Pharmaceuticals (Chairman) and Urovant Sciences, each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Clementia Pharmaceuticals, Armo BioSciences, Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Cyclacel Pharmaceuticals, Eckerd Pharmacy, Regado Biosciences, NephroGenex and several others. Mr. Legault served as Chairman of NephroGenex from 2012 through 2013 and Chief Executive Officer from 2014 through 2016 as Chief Executive Officer of Prosidion from 2010 through 2012 and Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 through 2010. His prior senior executive experience also includes serving as President of Eckerd Pharmacy and as Executive Vice President and Chief Administrative Officer of Rite Aid Corporation. Mr. Legault studied at McGill University, HEC Montreal and Harvard Business School. He holds an MBA, BAA, CA, CPA and Six Sigma Green Belt diplomas.- Pierre Legault ，2012十一月以来担任Nephrogenex执行董事长，这是专注治疗糖尿病肾病的制药公司；自2012四月起，担任Stone Management LLC总裁和首席执行官，该公司专注于业务开发和董事协助领域。2010-2012，他是英国中等规模生物技术公司Prosidion Ltd首席执行官，该公司是Astellas Pharmaceuticals的全资子公司。2009-2010他担任另一家中等规模生物技术公司 OSI Pharmaceuticals执行副总裁，首席财务官和财务总监。2007六月至2009，他担任财富500强医药零售公司 Rite Aid Corporation高级执行副总裁和首席行政官。此前，他在赛诺菲-安万特公司及其前身公司担任了多个高级职务，任期超过15年。最近的职务是该公司大型全球业务部的全球总裁，任期2003至2005。之前曾担任的职务包括，2000-2003，安万特制药高级副总裁，代理首席执行官；1998-2000， Hoechst Marion Roussel财务全球高级副总裁，财务总监；1997-1998，Marion Merrell Dow北美区财务，IT管理的高级副总裁和首席财务官；1990-1996， Marion Merrell Dow Pharmaceutical加拿大分部的高级副总裁和首席财务官。另外，他仍供职于一些上市公司，私营公司，非营利公司的董事会和审计委员会，以及一些咨询委员会，其中包括：OSI Investment Holdings GMBH （董事长）， 一个风险投资公司（2009-2012）， Cyclacel Pharmaceutical Inc.， 一个上市制药公司（2006-2008）， PJC Inc.， 一个药品销售上市公司（2005-2007）， 以及其它一些董事会。他曾在哈佛商学院，麦克吉尔大学和蒙特利尔大学学习，并拿到了美术和建筑学士学位，工商管理硕士学位，注册会计师资格。
- Pierre Legault is a Class I director who has served as a member of our board of directors since January 2017. Mr. Legault also serves on the board of Bicycle Therapeutics Chairman, Poxel Pharmaceuticals (Chairman) and Urovant Sciences, each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Clementia Pharmaceuticals, Armo BioSciences, Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Cyclacel Pharmaceuticals, Eckerd Pharmacy, Regado Biosciences, NephroGenex and several others. Mr. Legault served as Chairman of NephroGenex from 2012 through 2013 and Chief Executive Officer from 2014 through 2016 as Chief Executive Officer of Prosidion from 2010 through 2012 and Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 through 2010. His prior senior executive experience also includes serving as President of Eckerd Pharmacy and as Executive Vice President and Chief Administrative Officer of Rite Aid Corporation. Mr. Legault studied at McGill University, HEC Montreal and Harvard Business School. He holds an MBA, BAA, CA, CPA and Six Sigma Green Belt diplomas.